Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

Sonida Senior Living, Inc. (NYSE:SNDA) Q1 2025 Earnings Call Transcript May 12, 2025 Sonida Senior Living, Inc. beats earnings expectations. Reported EPS is $-0.77, expectations were $-0.95 ...

SAN DIEGO, CA – Travere Therapeutics, Inc. (NASDAQ: TVTX), a biopharmaceutical company with a market capitalization of $1.88 billion, has announced that the U.S. Food and Drug Administration (FDA) has ...

The sNDA submission comes amid the company’s efforts to provide treatment options for rare kidney disorders and follows the successful commercial launch of FILSPARI in IgAN, another rare kidney ...

Such forward-looking statements include, but are not limited to, references to: statements regarding the FDA’s review of the Company’s sNDA for FILSPARI in FSGS, and expectations regarding the ...

Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sonida Senior Living Q1 2025 Earnings Call.

We have great hope to potentially bring FILSPARI as the first approved treatment for patients with FSGS and this sNDA submission is an important next step toward that goal. We look forward to the ...

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...

Travere submitted an sNDA to FDA for FILSPARI, potentially first treatment for FSGS, based on positive clinical trial results.